The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.
Also called NCT05579418
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 350 participants
- Sponsor
- Registry
-
NCT05579418
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05579418. Randomized; no masking; primary purpose treatment. Start 2022-11-01 (anticipated); primary completion 2024-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
- Condition
- STEMI
- Condition
- Dyslipidemias
- Intervention (Drug)
- Evolocumab
- Lead sponsor
- Hamad Medical Corporation
Record details
- Record id
cardio:ct-nct05579418- Content hash
ff8b819cab7b78c1c240799fa333ca231994d0e35ae7b0a982407095c33ce56f